Meropenem Anfarm (Meropenem Anhydrous)

Meropenem works by binding to penicillin‑binding proteins on bacterial cell walls, inhibiting the final step of peptidoglycan cross‑linking. This disruption weakens the cell wall, leading to osmotic instability, cell lysis, and bacterial death. Its broad spectrum covers many Gram‑positive, Gram‑negative, and anaerobic bacteria, and it is stable against most β‑lactamases.

The specific dose of meropenem is determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and local susceptibility patterns. Dosing regimens are individualized and should follow the prescriber’s order and institutional guidelines.

Safety data for meropenem in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should assess each case individually and consider alternative therapies when appropriate.

To order Meropenem Anfarm, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. After verification, the team provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Meropenem shares a similar spectrum with other carbapenems such as imipenem‑cilastatin and ertapenem, but it offers a broader activity against Pseudomonas aeruginosa and certain resistant Gram‑negative organisms. Compared with non‑carbapenem β‑lactams, it provides greater stability against many β‑lactamases, making it a preferred option for multidrug‑resistant infections.

Meropenem Anfarm should be stored at 2‑8 °C in a refrigerator, protected from light, and never frozen. The product must remain in its original packaging until reconstitution. Once reconstituted, use the solution within the time frame specified in the package insert and discard any remaining solution after the recommended period.

Meropenem Anfarm is supplied as a sterile powder for intravenous infusion. It is reconstituted with a compatible diluent and administered by slow IV infusion, typically over 15–30 minutes. The infusion rate and duration are determined by the prescriber based on the clinical situation and patient tolerance.

Serious risks include severe allergic reactions such as anaphylaxis, seizure activity especially in patients with renal impairment or high plasma levels, and Clostridioides difficile‑associated colitis leading to potentially life‑threatening diarrhea. Prompt recognition and medical intervention are essential if any of these events occur.

Meropenem should be avoided in patients with a known hypersensitivity to carbapenems or other β‑lactam antibiotics. Caution is also advised for individuals with a history of seizures, severe renal impairment without dose adjustment, or those receiving concomitant valproic acid therapy due to increased neurotoxicity risk.